ZyVersa Therapeutics, Inc. ZVSA
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -24.49M | -24.95M | -25.70M | -8.29M | -8.84M |
| Total Depreciation and Amortization | -- | -- | 0.00 | 1.70K | 4.30K |
| Total Amortization of Deferred Charges | 57.20K | 57.20K | -- | -- | -- |
| Total Other Non-Cash Items | 18.52M | 18.26M | 18.52M | 777.90K | 760.30K |
| Change in Net Operating Assets | 1.77M | 1.52M | 1.26M | 2.39M | 2.56M |
| Cash from Operations | -4.14M | -5.11M | -5.92M | -5.12M | -5.52M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1.00M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.05M | 2.05M | 5.09M | 3.87M | 3.87M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -219.40K | 1.63M | 1.23M | 1.21M | 1.22M |
| Cash from Financing | 2.83M | 3.69M | 6.32M | 5.08M | 5.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.31M | -1.43M | 405.10K | -47.40K | -422.10K |